The company did not release any news during the period. Analysts cited confusion with trial data on the company's experimental anti-inflammatory drug used to treat patients undergoing heart surgery. This license allows PRI to operate under certain Chiron patents to screen for drug candidates that inhibit the hepatitis C virus. The financial terms of the license were not disclosed. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company.
Additional information is available upon request.
Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. BioSpace, and BioSpace's employees and officers, as well as Wayne Hummer Investments LLC, and Wayne Hummer Investments LLC 's employees and officers, in no way accept responsibility for any of the Newsletter's content. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. Also BioSpace, Inc. and Wayne Hummer Investments LLC may, from time to time solicit business from any company mentioned in this report.